Superiority of Rituximab Over Mycophenolate Mofetil in the Treatment of Pemphigus Vulgaris: A Step Further in Its Approval as a First-Line Treatment?

被引：0
作者：
Lemieux, Alexandre [1 ]
Saber, Melissa [1 ]
Cote, Benoit [1 ]
机构：
[1] Ctr Hosp Univ Montreal, Serv Dermatol, Dept Med, 1000 Rue St Denis, Montreal, PQ, Canada
来源：
JOURNAL OF CUTANEOUS MEDICINE AND SURGERY | 2022年 / 26卷 / 01期
关键词：
pemphigus; rituximab; mycophenolate mofetil; treatment; THERAPY;
D O I：
10.1177/12034754211035098
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：103 / 104
页数：2
相关论文
共 50 条
  • [41] Outcomes of Patients With Chronic Lymphocytic Leukemia Treated With First-Line Idelalisib Plus Rituximab After Cessation of Treatment for Toxicity
    Thompson, Philip A.
    Stingo, Francesco
    Keating, Michael J.
    Ferrajoli, Alessandra
    Burger, Jan A.
    Wierda, William G.
    Kadia, Tapan M.
    O'Brien, Susan M.
    CANCER, 2016, 122 (16) : 2505 - 2511
  • [42] First-line treatment with bendamustine and rituximab, in patients with intermediate-/high-risk splenic marginal zone lymphomas
    Castelli, Roberto
    Bergamaschini, Luigi
    Deliliers, Giorgio Lambertenghi
    MEDICAL ONCOLOGY, 2018, 35 (02)
  • [43] Rituximab Plus Chlorambucil As First-Line Treatment for Chronic Lymphocytic Leukemia: Final Analysis of an OpenLabel Phase II Study
    Hillmen, Peter
    Gribben, John G.
    Follows, George A.
    Milligan, Donald
    Sayala, Hazem A.
    Moreton, Paul
    Oscier, David G.
    Dearden, Claire E.
    Kennedy, Daniel B.
    Pettitt, Andrew R.
    Nathwani, Amit
    Varghese, Abraham
    Cohen, Dena
    Rawstron, Andy
    Oertel, Stephan
    Pocock, Christopher F. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (12) : 1236 - +
  • [44] Comparison of real costs in the French healthcare system in newly diagnosed patients with pemphigus for first-line treatment with rituximab vs. standard corticosteroid regimen: data from a national multicentre trial
    Hebert, V.
    Vermeulin, T.
    Tanguy, L.
    Tedbirt, B.
    Mignard, C.
    Benichou, J.
    Joly, P.
    BRITISH JOURNAL OF DERMATOLOGY, 2020, 183 (01) : 121 - 127
  • [45] First-Line Treatment of Hairy Cell Leukemia with Cladribine Followed by Rituximab Consolidation Significantly Improves Leukemia-Free Survival
    Amhez, Ghid
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S227 - S228
  • [46] Combination therapy with fludarabine and rituximab followed by alemtuzumab in the first-line treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma
    Hainsworth, John D.
    Vazquez, Elizabeth R.
    Spigel, David R.
    Raefsky, Eric
    Bearden, James D.
    Saez, Ruben A.
    Greco, F. Anthony
    CANCER, 2008, 112 (06) : 1288 - 1295
  • [47] Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial
    Davies, Andrew
    Merli, Francesco
    Mihaljevic, Biljana
    Mercadal, Santiago
    Siritanaratkul, Noppadol
    Solal-Celigny, Philippe
    Boehnke, Axel
    Berge, Claude
    Genevray, Magali
    Zharkov, Artem
    Dixon, Mark
    Brewster, Michael
    Barrett, Martin
    MacDonald, David
    LANCET HAEMATOLOGY, 2017, 4 (06): : E272 - E282
  • [48] Necitumumab for first-line treatment of advanced, squamous, non-small-cell lung cancer: a relevant step forward?
    Zugazagoitia, Jon
    Ponce, Santiago
    Paz-Ares, Luis
    TRANSLATIONAL LUNG CANCER RESEARCH, 2016, 5 (01) : 95 - 97
  • [49] The clinical effectiveness and cost-effectiveness of rituximab for the first-line treatment of chronic lymphocytic leukaemia: an evidence review of the submission from Roche
    Main, C.
    Pitt, M.
    Moxham, T.
    Stein, K.
    HEALTH TECHNOLOGY ASSESSMENT, 2010, 14 : 27 - 32
  • [50] The Combination of Rituximab and Bendamustine as First-Line Treatment Is Highly Effective in the Eradicating Minimal Residual Disease in Follicular Lymphoma: An Italian Retrospective Study
    Galimberti, Sara
    Ciabatti, Elena
    Ercolano, Giacomo
    Grassi, Susanna
    Guerrini, Francesca
    Cecconi, Nadia
    Rousseau, Martina
    Cervetti, Guilia
    Mazziotta, Francesco
    Iovino, Lorenzo
    Falzetti, Franca
    Falcinelli, Flavio
    Bosi, Alberto
    Rigacci, Luigi
    Kovalchuk, Sofia
    Vallisa, Daniele
    Macchia, Lucia
    Ciancia, Eugenio
    Petrini, Mario
    FRONTIERS IN PHARMACOLOGY, 2017, 8
12345